Profund Advisors LLC Sells 3,718 Shares of Kymera Therapeutics, Inc. $KYMR

Profund Advisors LLC reduced its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 29.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,831 shares of the company’s stock after selling 3,718 shares during the quarter. Profund Advisors LLC’s holdings in Kymera Therapeutics were worth $385,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Farther Finance Advisors LLC lifted its holdings in shares of Kymera Therapeutics by 642.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after acquiring an additional 540 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Kymera Therapeutics in the first quarter worth about $68,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Kymera Therapeutics by 15.8% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,516 shares of the company’s stock worth $110,000 after purchasing an additional 343 shares during the period. Advisors Asset Management Inc. lifted its stake in Kymera Therapeutics by 81.7% during the first quarter. Advisors Asset Management Inc. now owns 4,959 shares of the company’s stock worth $136,000 after purchasing an additional 2,230 shares during the period. Finally, AlphaQuest LLC acquired a new stake in Kymera Therapeutics during the second quarter valued at approximately $222,000.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. BTIG Research raised their target price on Kymera Therapeutics from $59.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. HC Wainwright lifted their price objective on Kymera Therapeutics from $70.00 to $84.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. B. Riley boosted their target price on shares of Kymera Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, October 24th. Mizuho started coverage on shares of Kymera Therapeutics in a research report on Tuesday, October 21st. They set an “outperform” rating and a $81.00 target price for the company. Finally, Morgan Stanley reissued an “overweight” rating and set a $73.00 price target on shares of Kymera Therapeutics in a report on Tuesday, November 4th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $69.75.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction on Monday, October 13th. The stock was sold at an average price of $59.19, for a total transaction of $295,950.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Jared Gollob sold 59,576 shares of Kymera Therapeutics stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $61.42, for a total value of $3,659,157.92. Following the completion of the sale, the insider directly owned 109,992 shares of the company’s stock, valued at $6,755,708.64. This trade represents a 35.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 206,910 shares of company stock worth $11,402,648. Company insiders own 16.01% of the company’s stock.

Kymera Therapeutics Stock Up 0.2%

Kymera Therapeutics stock opened at $63.63 on Friday. The stock has a 50-day simple moving average of $55.87 and a 200 day simple moving average of $45.97. The stock has a market capitalization of $4.58 billion, a price-to-earnings ratio of -17.72 and a beta of 2.32. Kymera Therapeutics, Inc. has a 12-month low of $19.44 and a 12-month high of $65.74.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.19). Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The company had revenue of $2.76 million during the quarter, compared to analyst estimates of $23.15 million. As a group, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.